ArticleOpen forum infectious diseases2025
Preswitch Regimens Associated With Weight Gain Among Persons With HIV who Switch to Integrase Inhibitor-Containing Regimens.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Determinants of Metabolic Syndrome in Virally Suppressed People Living with HIV: A Single-Center Comparative Analysis of Antiretroviral Regimens.Metabolites · 2026Article
- Predictors of Weight Gain in Individuals Living with HIV on Antiretroviral Therapy: A Cross-Sectional Study.Nursing reports (Pavia, Italy) · 2026Article
- Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Weight gain associated with integrase strand transfer inhibitors (INSTIs) is well documented. However, recent reports suggest that the observed weight gain among persons who switch to INSTIs may be associated with their preswitch regimen. Methods: We conducted retrospective analyses of persons with HIV on antiretroviral therapy who switched to a second-generation INSTI-containing regimen (bictegravir/dolutegravir) at the Duke Adult Infectious Diseases Clinic (Durham, NC, USA) between 2014 and 2021. The outcome was weight change, operationalized as percent weight change, absolute weight change (kg), gaining ≥5% of preswitch weight, and gaining ≥10% of preswitch weight. The primary exposure was preswitch regimen. Results: Our analysis included 750 persons. Cohort demographics were as follows: mean age (SD) 51 (11) years, 30% female at birth, 58% Black, 4% Hispanic ethnicity. At regimen switch, the mean CD4 count was 701 cells/mm Conclusions: Preswitch regimens containing efavirenz and TDF were associated with significant weight gain after switching to INSTI-based regimens. Our findings support the hypothesis that the weight gain observed with switching to INSTI-based regimens could be driven by stopping medications with weight-suppressing properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.